News

Actelion Presents Phase III Clinical Data at ATS Conference

Representatives from Actelion Pharmaceuticals Ltd will be presenting data from its Phase III GRIPHON and SERAPHIN studies at the American Thoracic Society (ATS) Conference 2015, held in Denver, Colorado. GRIPHON focused on the investigational drug selexipag (Uptravi®), while SERAPHIN focused on macitentan (Opsumit®). Both were used for patients with pulmonary…

Bellerophon Therapeutics Creates PH-Focused Scientific Advisory Board For INOpulse Programs

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, recently announced the formation of a Scientific Advisory Board (SAB) for its INOpulse technology that includes internationally recognized experts in the field of pulmonary hypertension (PH). The SAB will work closely with Bellerophon’s medical team while the firm prepares to further the advancement of its proprietary inhaled…

SteadyMed Seeks Orphan Drug Designation for PAH Drug

Specialty pharmaceutical company SteadyMed Ltd. has filled an application requesting orphan drug designation for its lead medical product, an investigational therapy to treat pulmonary arterial hypertension (PAH) called Trevyent. The application has been acknowledged by the U.S. Food and Drug Administration (FDA) and…

Team PHenomenal Hope Celebrates World PH Day

Tuesday, May 5th was World Pulmonary Hypertension Day, and to mark the occasion Team PHenomenal Hope, a cycling team comprised of medical and endurance professionals, shared with the PH community how to help raise awareness about pulmonary hypertension. Team PHenomenal Hope has been a highly effective advocate for the disease…

PHA Reveals Encouraging Results From National Call-In Day

The Pulmonary Hypertension Association (PHA) has shared the results of its recent National Call-In Day, reporting that the event was a major success thanks to the participation of the pulmonary hypertension community. The National Call-In Day took place on April 16th as part of an initiative to encourage PH advocates to call Congressional members and…

PHA Awards 12 PH Community Service Projects

The Pulmonary Hypertension Association (PHA) has awarded 12 community activists with the 2015 Tom Lantos Innovation in Community Service Award. The awardees, who will receive $5,000 each, are heading projects that are committed to raising awareness about pulmonary hypertension (PH). The Tom Lantos Innovation in Community Service Awards were created…

PH Association Creates Social Media Pin to Celebrate the World Pulmonary Hypertension Day Tomorrow, May 5

The Pulmonary Hypertension Association (PHA) recently announced in a press release that it will take the lead in a global effort to educate the general public about pulmonary hypertension on May 5, marked as World Pulmonary Hypertension Day. Pulmonary hypertension (PH) is a rare, debilitating, life-threatening condition characterized by an increase of blood…

PHA Accredits RI Hospital Pulmonary Hypertension Center

The Pulmonary Hypertension Association (PHA) has granted the PHA-accredited Center of Comprehensive Care (CCC) designation to the Pulmonary Hypertension Center at Rhode Island Hospital, making it one of the first centers of its type to receive the status in the country. The accreditation is given to centers for their excellency in…

Ascendis Pharma Reveals Results of Phase 1 Study of Pulmonary Arterial Hypertension Therapy TransCon Treprostinil

Ascendis Pharma A/S, a clinical stage biotechnology company focused on creating drug candidates by improving existing drugs, recently announced results from its Phase 1 single ascending dose trial of TransCon Treprostinil, which produced a dose-dependent increase in plasma treprostinil levels. However, results from the study showed that the tolerability of treprostinil…


A Conversation With Rare Disease Advocates